AGXT2 and hepatocellular carcinoma: In contrast, in the immune-suppressed TME, increased expression of AGXT2 has been shown to reduce intracellular cholesterol levels in HCC cells, downregulate LDL receptor (LDLR), and upregulate PCSK9 expression [24,25].